RGS18 and neoplasm: Importantly, it has recently been shown that circulating tumour cells are protected from NK-cell mediated clearance via NKG2A:HLA-E interactions, with HLA-E expression promoted by platelet-derived RGS18 and NKG2A blockade able to restore NK function and prevent tumour metastasis in vivo [114].